| Mental Retardation |
2020-001878-29: Impact of a working method on traumatic memory under PROPRanolol in ADOlescents with post-traumatic stress syndrome (PROPRADO) Impact d’une méthode de travail sur la mémoire traumatique sous PROPRanolol chez des ADOlescents atteints du syndrome de stress post-traumatique (PROPRADO) |
|
|
| Not yet recruiting | 3 | 74 | Europe | chlorhydrate de propranolol, cellulose microcristalline, propranolol, placebo, Capsule | Rennes University Hospital, Hospital clinical research programme | post-traumatic stress disorder trouble du stress post-traumatique, PTSD TPST, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004006-26: Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 years of age) with Schizophrenia |
|
|
| Ongoing | 3 | 330 | Europe | cariprazine, RGH-188, Capsule, hard | Allergan Ltd, Allergan Ltd. | Adolescent Patients (13 to 17 years of age) with Schizophrenia, Adolescent Patients (13 to 17 years of age) with Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2011-005320-17: Effects of agomelatine on emotional experiences in depressed adults patients as compared to escitalopram |
|
|
| Ongoing | 3 | 500 | Europe | S20098, S20098, Capsule, VALDOXAN, SEROPLEX, CIPRALEX | Institut de Recherches Internationales Servier, SRDL, Servier Research and Develpment | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2013-002055-15: CONTROLLED MULTICENTER STUDY ON THE MOOD-STABILIZING EFFECT OF MEMANTINE IN BIPOLAR I DISORDERS STUDIO MULTICENTRICO CONTROLLATO SULL'EFFETTO PROFILATTICO DELLA MEMANTINA NEL DISTURBO BIPOLARE DI TIPO I |
|
|
| Ongoing | 3 | 106 | Europe | Coated tablet, EBIXA, LAMOTRIGINE DOC -GENERIC | UNIVERSITY OF SASSARI, UNIVERSITY OF SASSARI | BIPOLAR I MOOD DISORDERS DISTURBO DELL'UMORE DI TIPO I, MANIC-DEPRESSIVE ILLNESS MALATTIA MANIACO-DEPRESSIVA, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2010-024202-34: group-therapy, autism and oxytocin - an investigation with the question "Does oxytocin (OT) enhance therapy effects in autism?“ Gruppentherapie, Autismus und Oxytocin - Eine Untersuchung, mit der Fragestellung: "Erhöht Oxytocin den Therapieeffekt bei Autisten?" |
|
|
| Ongoing | 3 | 210 | Europe | SyntocinonⓇSpray, 11.266, Nasal spray, SyntocinonⓇSpray | Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit | high-functioning autismus spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F84.1) Hochfunktionale Autismus-Spektrum-Störung: Frühkindlicher Autismus (F84.0), Asperger-Syndrom (F84.5), Atypischer Autismus (F84.1), autism Autismus, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2014-001157-17: Efficacy of intranasal administration of haloperidol compared to intramuscular administration in agitated schizophrenic patients Eficacia de la administración de haloperidol intranasal comparada con la administración intramuscular en pacientes esquizofrénicos agitados |
|
|
| Ongoing | 3 | 40 | Europe | Nebulisation solution, Solution for injection | Fundació Parc TaulÃ, Fundació Parc Taulà | Agitation in schizophrenic patients Agitación en pacientes esquizofrénicos, Agitation in schizophrenic patients Agitación en pacientes esquizofrénicos, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 3 | 100 | Europe | tolcapone, Coated tablet, Tasmar | MediPsych SA, General Secretary for Research and Technology-Dept. of Education, MediPsych SA | schizophrenia, schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2014-003008-53: Clonidine added to the current treatment of therapy resistant schizophrenia Een toevoeging van clonidine aan de huidige behandeling van therapie-resistente schizofrenie |
|
|
| Ongoing | 3 | 75 | Europe | Clonidine HCL, RVG nr: 19845=56917, Capsule, Clonidine HCL | University Medical Center Utrecht | Schizophrenia, schizophreniform disorder, schizoaffective disorder Schizofrenie, schizofreniforme stoornis, schizoaffectieve stoornis, Schizophrenia, psychosis-related disorder Schizofrenie, psychose-gerelateerde stoornis, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2012-004298-20: The effect of methylphenidate on executive functioning in amphetamine dependent individuals with ADHD |
|
|
| Ongoing | 3 | 24 | Europe | methylphenidate, Capsule, Concerta 36 mg depottablett | Stockholm Centre for Dependency Disorders, Stockholm Centre for Dependency Disorders | Amphetamine dependence, Patients who fulfil DSMIV/5 criteria for amphetamine dependence, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Not yet recruiting | 3 | 20 | Europe | Injection, Solution for infusion, Nitropress - SODIUM NITROPRUSSIDE, 5% dextrose | Clinirx Tangent Research, Stanley Medical Research Institute | schizophrenia, Psychotic disorders, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 3 | 60 | Europe | Pioglitazona, A10BG03, Tablet | Hospital Universitario Araba (Sede Santiago), No | Bipolar disorder Trastorno bipolar, Bipolar disorder Trastorno bipolar, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2014-004094-17: Does adding cannabidiol (a component of cannabis) enhance the treatment of phobias where patients are confronted with their fears (exposure treatment). Wordt behandeling van fobische angststoornissen waarbij patiënten hun angst opzoeken (exposurebehandeling) effectiever als de cannabiscomponent cannabidiol wordt toegediend voorafgaand aan een sessie? |
|
|
| Ongoing | 3 | 90 | Europe | Cannabidiol, Capsule | Universiteit Utrecht, ZonMw | Phobic anxiety disorders: either generalized social phobia or panic disorder with agoraphobia. Patiënten met of een gegeneraliseerde sociale fobie of een paniekstoornis met agorafobie., Patients who experience severe anxiety in many social situations (such as giving a presentation or going to a party), and patients who have panic attacks when in an open field or surrounded by people. Patiënten die erg angstig zijn in verschillende sociale situaties (bijv. presentaties of feestjes) en patiënten met paniekaanvallen als ze in een open veld of omringd door mensen zijn., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2011-003432-32: Etude d'efficacité et de tolérance du Topiramate dans le Prader Willi |
|
|
| Not yet recruiting | 3 | 125 | Europe | Topiramate, Capsule, Topiramate | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Patients de plus de 12 ans présentant un Syndrome de Prader Willi, Syndrome de Prader Willi, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2009-015895-87: Application of zileuton (Zyflo CR) in patients with Sjögren Larsson Syndrome |
|
|
| Ongoing | 3 | 20 | Europe | zileuton, Zyflo CR, Zyflo CR | UMC St Radboud | Sjögren Larsson syndrome (SLS) is an autosomal recessive inherited neurometabolic disorder which is characterized by a clinical triad of congenital ichthyosis, spastic di- or tetraplegia and mental retardation. A disturbance of lipid metabolism due to deficiency of the microsomal fatty aldehyde dehydrogenase (FALDH) underlies SLS. | | | | |
2015-002181-23: Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depressive Disorder. |
|
|
| Ongoing | 3 | 484 | Europe, RoW | Agomelatine, Fluoxetine, S20098, Film-coated tablet, Oral solution, Valdoxan, Fluoxetine | Institut de Recherche International Servier, ADIR | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2015-003957-16: Oral ketamine for treating depression Orale ketamine als aanvullende behandeling bij patiënten met een therapieresistente depressie |
|
|
| Ongoing | 3 | 128 | Europe | Capsule | University Medical Centre Groningen, ZonMw | Treatment resistant major depressive disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-000215-32: Effect of Pycnogenol® on Attention-Deficit Hyperactivity Disorder (ADHD). Effect van Pycnogenol® op Aandachtstekort Hyperactiviteitsstoornis (ADHD). |
|
|
| Ongoing | 3 | 144 | Europe | Pycnogenol, Medikinet Retard, PYC, Capsule, Capsule, hard, Medikinet Retard | University of Antwerp, Horphag Research, University of Antwerp | Attention-deficit hyperactivity disorder (ADHD) ADHD, ADHD: hyperactivity and/or low concentration ADHD: hyperactiviteit en/of gebrek aan concentratie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2014-004475-23: Testosterone and exposure therapy for SAD Testosteron en exposuretherapie voor sociale angststoornis |
|
|
| Ongoing | 3 | 46 | Europe | Testosterone, Sublingual spray, solution | Radboud University Nijmegen, Radboud University Nijmegen, Pro Persona | Social Anxiety Disorder (Social Phobia) Sociale Angststoornis (Social Phobia), Social Anxiety Sociale angst, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2013-004881-33: Multicentre trial in to investigate the usage of antidepressant and antipsychotics (with / without approval) in patients at the age of children and adolescents Groß an gelegte, einfache offene klinische Studie mit mehreren teilnehmenden Prüfzentren zur Anwendung von Antidepressiva und Neuroleptika (mit /ohne Zulassung) |
|
|
| Ongoing | 3 | 1000 | Europe | Tablet, Abilify, Zyprexa, Leponex, Seroquel, Risperdal, Zeldox, Melneurin, Dipiperon, Saroten, Cipramil, Anafranil, Aponal, Cymbalta, Cipralex, Fluctin, Fevarin, Tofranil, Ludiomil, Remergil, Nortrilen, Paroxat, Zoloft, Stangyl, Trevilor | Universitätsklinikum Würzburg, Kompetenznetz TDM-KJP e.V., BfArM | therapeutic use in clinical practise Therapeutische Anwendung im klinischen Alltag, therapeutic use in clinical practise Therapeutische Anwendung im klinischen Alltag, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-000061-23: A 12-Week Extension Study looking at the effects of Lurasidone (SM-13496) in Subjects with Schizophrenia |
|
|
| Ongoing | 3 | 283 | Europe | Lurasidone, SM-13496, Film-coated tablet, Latuda | Sunovion Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-002859-19: Withdrawing off-label antipsychotics in people with intellectual disabilities: why does it fail? Antipsychotica afbouwen bij mensen met een verstandelijke beperking: waarom lukt het niet? |
|
|
| Ongoing | 3 | 126 | Europe | Risperidone, Pipamperone, Oral liquid, Risperidone, Pipamperone | Erasmus MC, Abrona, Ipse de Bruggen, Amarant | People with challenging behavior and off-label antipsychotic use Mensen met een verstandelijke beperking en gedragsproblemen waarvoor offlabel antipsychotica gebruik, People with challenging behavior and off-label antipsychotic use Mensen met een verstandelijke beperking en gedragsproblemen waarvoor offlabel antipsychotica gebruik, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-003437-18: A phase 3 study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Schizophrenia |
|
|
| Ongoing | 3 | 308 | Europe | Pimavanserin, ACP-103, Tablet | ACADIA Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc. | Schizophrenia, Chronic, debilitating mental illness characterized by disturbances in thinking, emotional reaction, and behavior, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-003766-27: The DREAMING study: Efficacy of low dose amitriptyline and mirtazapine for insomnia disorder |
|
|
| Ongoing | 3 | 156 | Europe | amitriptyline, mirtazapine, Film-coated tablet, amitriptyline, mirtazapine | VU University Medical Centre, ZonMw | Insonnia disorder, Sleeping disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-003074-14: A study to evaluate Samyr effectiveness and safety profile. The study is done by comparing that Samyr injection is better than placebo injection in subjects with depression which are treated regularly with antidepressant tablet treatment. Uno studio per valutare l'efficacia e il profilo di sicurezza di Samyr. Lo studio viene effettuato confrontando che l'iniezione di Samyr ¿ migliore dell'iniezione di placebo in soggetti con depressione trattati regolarmente con il trattamento con compresse antidepressive. |
|
|
| Ongoing | 3 | 468 | Europe | SAMYR, SAMYR, Powder and solvent for solution for injection, SAMYR - 400 MG/5 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 5 FLACONCINI POLVERE + 5 FIALE SOLVENTE 5 ML | MYLAN INC., Mylan Inc. | Major Depression Disorders Disturbo Depressivo Maggiore, Major Depression Depressione maggiore, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-001514-15: Effects of early clozapine treatment on remission rates in acute schizophrenia (EARLY) Effekte der frühzeitigen Applikation von Clozapin auf die Remissionsrate bei akuter Schizophrenie |
|
|
| Not yet recruiting | 3 | 220 | Europe | Clozapin 1A-Pharma, Zyprexa Lilly, Capsule, hard | Bezirkskliniken Schwaben, DFG Grant Number HA 6091/4-1, project number: 316096538 | Schizophrenia Schizophrenie, Schizophrenia Schizophrenie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 3 | 250 | RoW | LY03004, RISPERDAL® CONSTA®, TEST, REFERENCE, Powder and solvent for prolonged-release suspension for injection, EU Risperdal® Consta® | Nanjing Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., Ltd., Luye Pharma Group, Ltd. | schizophrenia, schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004460-63: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Sublocade, Buprenorphine, METHADONE, Buprenorphine-Naloxone, Espranor Oral lyophilisate, RBP-6000, Solution for infusion in pre-filled syringe, Sublingual tablet, Oral liquid, Oral lyophilisate, SUBOXONE, Espranor | South London and Maudsley NHS Foundation Trust, King's College London, INDIVIOR UK | Opiod addiction, Opiod Addiction, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001520-35: Treating Insomnia with Medical comorbidity: Low dose Amitriptyline vs cognitive behavioral therapy Een lage dosering amitriptyline en cognitieve gedragstherapie bij langdurige slapeloosheid voor patiënten met een medische aandoening |
|
|
| Ongoing | 3 | 190 | Europe | amitriptyline, Tablet, AMITRIPTYLINE HCl 10 – 25 MG TEVA | Hospital Gelderse Vallei, Amsterdam Univesity Medical Centre | Insomniadisorder Insomniastoornis, Insomnia, sleeplesness Chronische slapeloosheid, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 3 | 290 | Europe | Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg, Tablet, Pramipexole 0.18mg Tablets, Pramipexol Aurobindo 0.18 mg, Pramipexole Aurobindo 0.18 mg, Pramipexole 0.7mg Tablets, Pramipexol Aurobindo 0.7 mg, Pramipexole Aurobindo 0.7 mg | Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, NIHR HTA programme | Bipolar disorder (BD), A mental disorder that causes periods of depression and periods of abnormally elevated mood., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002213-19: A randomised study to evaluate Lurasidone versus Placebo in improving cognitive functioning in patients with Bipolar Disorder |
|
|
| Ongoing | 3 | 300 | Europe | Latuda, n/a, Film-coated tablet, Latuda | University of British Columbia, University of British Columbia | Euthymic Bipolar disorder, Bipolar Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-003109-92: A study to look at Ketamine as an additional treatment for people with depression |
|
|
| Not yet recruiting | 3 | 104 | Europe | Solution for injection/infusion, Solution for injection, Ketalar, Hypnovel | Trinity College Dublin, Health Research Board | Major Depression, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002640-25: A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 546 | Europe | Sage-217, Capsule | Sage Therapeutics, Inc., Sage Therapeutics, Inc. | MAJOR DEPRESSIVE DISORDER, MAJOR DEPRESSIVE DISORDER, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003251-37: A study to evaluate the safety of Pimavanserin therapy in subject with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 280 | Europe | Pimavanserin, ACP-103, Film-coated tablet | ACADIA Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002749-12: Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression |
|
|
| Not yet recruiting | 3 | 514 | Europe | ITI-007, Capsule | Intra-Cellular Therapies, Inc. (ITI), Intra-Cellular Therapies, Inc. (ITI) | Major depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression), Bipolar Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-002787-32: Antidepressant for the prevention of DEPression following first episode Psychosis trial |
|
|
| Not yet recruiting | 3 | 508 | Europe | Sertraline, Film-coated tablet | University of Birmingham, National Institute for Health Research | Patients with First Episode Psychosis., Patients who are experience symptoms of psychosis for the first time., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000784-23: The effects of esketamine and treatment expectation in acute major depressive disorder Die Effekte von Behandlungserwartung an Esketamin vs. Placebo bei akuter majorer Depression |
|
|
| Not yet recruiting | 3 | 176 | Europe | Ketanest S, Solution for injection, Ketanest S | Philipps-Universität Marburg, Deutsche Forschungsgemeinschaft (DFG) | To unravel the neural correlates of the interaction between positive expectation (high/low) and single dose antidepressant treatment (verum/placebo) with esketamine in patients with major depressive disorder, To unravel the interaction between positive expectation and single dose antidepressant treatment with esketamine in patients with major depressive disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-001424-34: A study to Evaluate SAGE-217 for the Treatment of Adults with Post-Partum Depression |
|
|
| Not yet recruiting | 3 | 192 | Europe | SAGE-217, Capsule, hard | Sage Therapeutics, Inc., Sage Therapeutics, Inc. | POSTPARTUM DEPRESSION, POSTPARTUM DEPRESSION, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003252-20: A study of the safety of pimavanserin in adult subjects with major depressive disorder |
|
|
| Not yet recruiting | 3 | 420 | Europe | Pimavanserin, ACP-103, Film-coated tablet | ACADIA Pharmaceuticals Inc, Acadia Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, Acadia Pharmaceuticals Inc | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-005956-39: Treatment of pediatric Post-traumatic Stress Disorder with memory reactivation under the influence of propranolol: A randomized placebo-controlled trial Traitement du Trouble Stress Post-Traumatique pédiatrique par réactivation du souvenir traumatique sous propranolol : une étude randomisée contrôlée versus placebo. |
|
|
| Not yet recruiting | 3 | 92 | Europe | Propanolol, Syrup, Propanolol | CHU Toulouse, French Ministery of Health | Post-traumatic Stress Disorder Stress post traumatique, Post-traumatic Stress Disorder Stress post traumatique, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-004984-31: Nitrous Oxide in Resistant Depression in Elderly Subjects: A Randomized, Double-blind, Comparator Trial Protoxyde d’Azote dans la Dépression Résistante du Sujet Âgé: un essai randomisé en double aveugle avec comparateur |
|
|
| Not yet recruiting | 3 | 60 | Europe | Medicinal gas, compressed, KALINOX® (MEOPA) | CHRU TOURS, DGOS | Resistant Depression in the Elderly Subject Dépression résistante chez le sujet âgé, Resistant Depression in the Elderly Subject Dépression résistante chez le sujet âgé, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-003739-62: BOOSTCAMP: Boosting the endocannabinoid system before the treatment of anxiety symptoms |
|
|
| Ongoing | 3 | 82 | Europe | Cannabidiol (CBD), Capsule | University Medical Center Utrecht, The Brain Research and Innovation Centre / University Medical Center Utrecht | PTSD and anxiety disorders, PTSD and anxiety disorders, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-002011-61: Riluzole as treatment for psychotic and cognitive symptoms in 22q11.2 deletion syndrome Riluzol als behandeling voor psychotische en cognitieve symptomen in 22q11.2 deletie syndroom. |
|
|
| Ongoing | 3 | 45 | Europe | Riluzole, EMEA/H/C/000109, Tablet, Rilutek | Academisch ziekenhuis Maastricht, Academisch ziekenhuis Maastricht | 22q11.2 deletion syndrome 22q11.2 deletie syndroom, 22q11.2DS 22q11.2DS, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003164-31: The purpose of this study is to look into the safety and efficacy ofcariprazine as an add-on medication in the treatment of major depressivedisorder. |
|
|
| Not yet recruiting | 3 | 750 | RoW, Europe | Cariprazine, Capsule | Allergan Ltd., Allergan Sales LLC | Major Depressive Disorder, Clinical Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001192-17: A Study to Assess the Efficacy and Safety of Lumateperone as Add on Therapy in the Treatment of Patients with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 470 | RoW, Europe | Lumateperone, ITI-007, Capsule | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-002068-30: Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia |
|
|
| Not yet recruiting | 3 | 800 | Europe | Lumateperone, ITI-007, Capsule, Caplyta | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002778-30: Double-blind, randomised, multicenter study to evaluate the efficacy and safety of memantine in adolescents with Bipolar Disorder Studio multicentrico randomizzato in doppio cieco per valutare l'efficacia e la sicurezza della memantina negli adolescenti con Disturbo Bipolare |
|
|
| Not yet recruiting | 3 | 68 | Europe | MEMANTINA ACCORD, [NA], Film-coated tablet, MEMANTINA ACCORD - 10 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PE/PVDC/ALLUMINIO) - 56 COMPRESSE | IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA, Ministero della Salute | Bipolar Disorder Disturbo Bipolare, Bipolar Disorder in adolescents Disturbo bipolare negli adolescenti, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001172-41: A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 760 | RoW, Europe | Lumateperone, ITI-007, Capsule, CAPLYTA | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001212-29: A Study to Assess the Efficacy and Safety of Lumateperone as Add on Therapy in the Treatment of Patients with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 470 | Europe, RoW | Lumateperone, ITI-007, Capsule | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-002572-39: Effects of add-on Celecoxib treatment in patients with schizophrenia spectrum disorders and inflammatory cytokine profile (TargetFlame) Evaluation der Effektivität der add-on Behandlung von Celecoxib bei Menschen mit einer Schizophrenie und inflammatorischen Zytokin-Profil |
|
|
| Not yet recruiting | 3 | 109 | Europe | Celecoxib, Capsule, hard, Celecoxib | Bezirkskliniken Schwaben, Era PerMed BMBF | Schizophrenia Schizophrenia, Schizophrenia Schizophrenie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004532-30: A 24 month Open-Label, international study of paliperidone 6 month formulation in patients with who have completed study R092670PSY3015 Schizophrenia is a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs). |
|
|
| Not yet recruiting | 3 | 180 | Europe | 1092mg paliperidone palmitate extended release suspension for injection (eq. 700 mg paliperidone), 1560 mg paliperidone palmitate extended release suspension for injection (eq. 1000 mg paliperidone), R092670, Prolonged-release suspension for injection in pre-filled syringe | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC, Janssen-Cilag SpA, Janssen-Cilag International NV | Schizophrenia, Schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-004193-64: A Study to assess the effectivenss of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia. |
|
|
| Not yet recruiting | 3 | 402 | Europe | Brilaroxazine, RP5063, Tablet | Reviva Pharmaceuticals Holdings Inc., Reviva Pharmaceuticals Holdings Inc. | Acute Exacerbation of Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-003714-39: Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia |
|
|
| Not yet recruiting | 3 | 400 | Europe | Valbenazine, NBI-98854, Capsule | Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2021-003850-21: Treating depression with anti-inflammatory drugs Behandeling van depressie met ontstekingsremmers |
|
|
| Ongoing | 3 | 140 | Europe | Celecoxib, Capsule, hard, Celecoxib | Amsterdam UMC, location VUmc, Amsterdam UMC, location VUmc, Hersenstichting | Immuno metabolic Depression Immuno metabole depressie, Depression with imflammation and energy-related symptoms Depressie met onstekingen en energie-gerelateerde symptomen, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
ChiCTR2300069249: Effect of Esketamine on depression and perioperative neuropsychiatric disorders in patients with malignant tumors |
|
|
| Recruiting | 3 | 240 | | After anesthesia induction, group E was given 0.5mg/kg Esketamine (esketamine diluted to 10mg/ml) and 100ml postoperative analgesic pump, and the analgesic formula was Esketamine 2mg/kg(Esketamine diluted to 10mg/ml) + Sufentanil 2.5μg/kg+ flurbiprofen ester 2mg/kg+ tolanisetron 10mg+ normal saline ;After anesthesia induction, group C was given 0.05ml/kg normal saline and 100ml postoperative analgesic pump. The analgesic formula was Sufentanil 2.5μg/kg+ flurbiprofen ester 2mg/kg+ toranisetron 10mg+ normal saline | Affiliated Tumor Hospital of Guangxi Medical University; Affiliated Tumor Hospital of Guangxi Medical University, Mentor funds | Perioperative neurocognitive dysfunction | | | | |
2022-001563-26: Drug treatment with Pramipexole for lack of interest and motivation in depression. Läkemedelsbehandling med pramipexol vid symptomen bristande intresse och nedsatt motivation vid depression. |
|
|
| Not yet recruiting | 3 | 120 | Europe | Pramipexol Stada prolonged-release tablets 0,26 mg, 0,52 mg, 1,05 mg and 2,1 mg, Prolonged-release tablet, Pramipexol Stada prolonged-release tablets | Region Skåne, Vetenskapsrådet, ALF, Kungliga fysiografiska sällskapet, Olle Engkvists Stiftelse, Craafordstiftelsen, Ellen och Henrik Sjöbrings Minnesfond, O.M. Perssons Minnesfond, Hjärnfonden | The effect of nine weeks of treatment with the dopamine agonist Pramipexole in patients with depression with clinically significant anhedonia will be evaluated with symptom rating scales, blood and cerebrospinal fluid samples, neuroimaging, and neuropsychological testing. Thus, this study focuses on patients with substantial anhedonia and these patients are identified through validated assessment scales. Behandlingseffekten av nio veckors behandling med dopaminagonisten pramipexol för patienter med depression med kliniskt signifikant anhedoni kommer att utvärderas med symptomskattningar, blod- och likvorprover, neuroimaging och neuropsykologisk testning. Studien riktar sig alltså till patienter med uttalad anhedoni och dessa patienter identifieras via vedertagna skattningsskalor., The patients treated in this study must have an ongoing depression with clearly lowered interest and decreased motivation (i.e. strong anhedonia). Patienterna som behandlas i denna studie ska ha en pågående depression med tydligt sänkt intresse och minskad motivation (d.v.s. uttalad anhedoni)., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001515-10: A Phase 3 study to assess the safety of KarXT and how it helps in reoccurrence prevention in people with psychosis associated with Alzheimer’s Disease Dementia as compared to placebo Un estudio de fase 3 para evaluar la seguridad de KarXT y cómo ayuda aprevenir la recurrencia en personas con psicosis asociada con la demenciapor enfermedad de Alzheimer en comparación con un placebo |
|
|
| Not yet recruiting | 3 | 380 | Europe, RoW | KarXT, [--], [n/a], Capsule, hard | Karuna Therapeutics, Karuna Therapeutics, Inc., Karuna Therapeutics, Karuna Therapeutics, Inc. | Psychosis Associated with Alzheimer’s Disease Dementia Psicosis asociada con la demencia de la enfermedad de Alzheimer, Delusions or hallucinations associated with mild to severe Alzheimer’s disease memory loss Delirios o alucinaciones asociados con la pérdida de memoria leve agrave de la enfermedad de Alzheimer, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001666-35: A rollover study for subjects that complete Kar-012, to assess Long-term Safety and Tolerability of KarXT in combination with specified atypical antipsychotics in Subjects with Inadequately Controlled Symptoms of Schizophrenia |
|
|
| Not yet recruiting | 3 | 280 | Europe | KarXT, Capsule, hard | Karuna Therapeutics, Inc., Karuna Therapeutics, Inc. | Schizophrenia, Brain disorder that causes altered state that affects a person's ability to think, feel, and behave clearly., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001665-12: A Phase 3 study to assess the safety and effectiveness of KarXT in combination with specific approved atypical antipsychotic medications to reduce the signs and symptoms of Schizophrenia in adult subjects. |
|
|
| Not yet recruiting | 3 | 400 | Europe | KarXT, Capsule, hard | Karuna Therapeutics, Inc., Karuna Therapeutics, Inc. | Schizophrenia, brain disorder that causes altered state of affect a person's ability to think, feel, and behave clearly., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000430-42: a study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. |
|
|
| Ongoing | 3 | 840 | Europe, RoW | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD) Major depressziós zavar (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000461-41: A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant. |
|
|
| Not yet recruiting | 3 | 538 | RoW, Europe | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-003073-33: A research study to compare the antidepressant ability and safety of Samyr® tablets versus placebo tablets as an adjunct to additional antidepressant treatment in patients with major depressive disorder (MDD) Uno studio di ricerca per confrontare l'abilità antidepressiva e la sicurezza delle compresse di Samyr® rispetto alle compresse di placebo in aggiunta al trattamento con antidepressivi aggiuntivo nei pazienti con disturbo di depressione maggiore (MDD) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Samyr, [NA], Gastro-resistant tablet, SAMYR - 400 MG COMPRESSE GASTRORESISTENTI20 COMPRESSE | Mylan Inc., Mylan Inc. | Major Depression Disorder Disturbo Depressivo Maggiore, Major Depression Depressione maggiore, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001865-11: A Study to Test if TV-44749 is Effective in Relieving Schizophrenia |
|
|
| Not yet recruiting | 3 | 640 | Europe | Olanzapine, TV44749, Powder and solvent for prolonged-release suspension for injection | Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc. | Schizophrenia is a serious mental disorder in which people interpret reality abnormally. It is a severely debilitating psychotic disorder characterized by positive symptoms (eg, delusions, hallucinations, and grossly disorganized behavior) and negative symptoms (eg, affective flattening, alogia, and avolition)., Schizophrenia is a mental disorder that may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning and can be disabling, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000439-22: A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant. |
|
|
| Ongoing | 3 | 538 | Europe, RoW | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000688-22: A phase III study evaluating the efficacy and safety of Silexan in patients with mild to moderate depression Eine Phase 3 Studie zum Nachweis der Wirksamkeit und Sicherheit von Silexan bei Patienten mit einer leichten bis mittelschweren Depression |
|
|
| Not yet recruiting | 3 | 498 | Europe | Silexan, sertralin-biomo 50 mg Filmtabletten, WS® 1265, Capsule, soft, Tablet, Lasea®, Sertralin-biomo 50 mg Filmtabletten | Dr. Willmar Schwabe GmbH & Co. KG, Dr. Willmar Schwabe GmbH & Co. KG | Major Depressive Disorder Akute Episode einer depressiven Erkrankung, Depression Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000405-83: A clinical study to evaluate iloperidone in the treatment of patients with acute manic episodes associated with Bipolar I Disorder Badanie kliniczne oceniające stosowanie iloperidonu w leczeniu pacjentów z ostrymi epizodami manii związanymi z chorobą dwubiegunową typu I |
|
|
| Not yet recruiting | 3 | 400 | Europe, RoW | Iloperidone, VYV-683, Capsule, Tablet | Vanda Pharmaceuticals Inc., Vanda Pharmaceuticals Inc. | Acute manic episodes associated with Bipolar I Disorder Ostre epizody manii związane z chorobą dwubiegunową typu I, Bipolar I Disorder Choroba dwubiegunowa typu I, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Recruiting | 3 | 800 | Europe, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 06/24 | 05/25 | | |
2018-004899-35: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148 |
|
|
| Not yet recruiting | 3 | 95 | US | Rexulti, Tablet, Rexulti | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Irritability Associated With Autism Spectrum Disorder, AutismAutism Spectrum DisorderASDIrritability, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-000723-40: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder ( Anchor ) |
|
|
| Not yet recruiting | 3 | 130 | US | Rexulti, Tablet, Rexulti | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Irritability Associated With Autism Spectrum Disorder (ASD), AutismIrritabilityAutism Spectrum DisorderASD, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
TIM-DePisT, NCT05946486: Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity. |
|
|
| Not yet recruiting | 3 | 174 | Europe | immunomodulatory treatment by rituximab | University Hospital, Bordeaux | Mental Disorder | 01/26 | 12/26 | | |
| Recruiting | 3 | 120 | Europe | Pramipexole, Placebo | Region Skane, Lund University | Psychiatric Disorders Mood, Anhedonia, Depression | 12/26 | 03/27 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
2017-001169-26: Evaluation of NaBen® (sodium benzoate) in treatment of schizophrenia in adults |
|
|
| Not yet recruiting | 2/3 | 348 | Europe | NaBen®(F.C.T.II), NaBen®(F.C.T.II), Film-coated tablet | SyneuRx International (Taiwan) Corp, SyneuRx International (Taiwan) Corp. | Treatment for Schizophrenia in Adults, Treatment for Schizophrenia in Adults, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-001170-42: Two-part Clinical Study to Evaluate the Safety and Efficacy of NaBen® in Adults with Refractory Schizophrenia |
|
|
| Not yet recruiting | 2/3 | 287 | Europe, RoW | NaBen®(F.C.T.II), NaBen®(F.C.T.II), Film-coated tablet | SyneuRx International (Taiwan) Corp, SyneuRx International (Taiwan) Corp | Treatment for Refractory Schizophrenia in Adults, Treatment for treatment-resistant Schizophrenia in Adults, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-006062-36: A Phase II/III, randomized, 4-week, placebo-controlled study, designed to determine the safety, tolerability, and efficacy of evenamide (NW-3509) in patients with chronic schizophrenia. |
|
|
| Ongoing | 2/3 | 196 | Europe, RoW | Evenamide, NW3509, Capsule, hard | Newron Pharmaceuticals S.p.A., NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A, Newron Pharmaceuticals S.p.A., Newron Pharmaceuticals S.p.A | Chronic schizophrenia, Chronic schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001333-38: Clinical trial to study the effect of an already authorized drug on other pathologies by administering it to people with a recent diagnosis of schizophrenia. Ensayo clínico para estudiar el efecto que tiene un fármaco ya autorizado en otras patologías administrándolo en personas con reciente diagnóstico de esquizofrenia. |
|
|
| Not yet recruiting | 2/3 | 50 | Europe | VORTIOXETINA, HALOPERIDOL, Pimozida, Olanzapina, Risperidona, Chlorpromazine, Thioridazine, Quetiapine, Ziprasidone, aripiprazole, N06AX26, N05AD01, NO5AG02, NO5A H03, NO5AX08, N05AA01, N05AC02, N05AH04, N05AE04, N05AX12, Tablet, Capsule, hard, BRINTELLIX | Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI), Consejería de salud | Early schizophrenia Esquizofrenia temprana, Newly evolving schizophrenia Esquizofrenia de reciente evolución, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-002093-34: Phase II / III, open-label, extension study designed to determine the long-term safety, tolerability and efficacy of evenamide (NW-3509) in patients with psychiatric disorders who participated in previous trials with evenamide. Studio di fase II/III, di estensione, in aperto, progettato per determinare la sicurezza a lungo termine, la tollerabilità e l'efficacia di evenamide (NW-3509) in pazienti con disturbi psichiatrici che hanno partecipato a precedenti studi con evenamide. |
|
|
| Not yet recruiting | 2/3 | 500 | Europe | Evenamide, [NW3509], Capsule, hard | NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A | Patients with psychiatric disorders who participated in a previous trial with evenamide. Pazienti con disturbi psichiatrici che hanno partecipato a una precedente sperimentazione con evenamide., Patients with psychiatric disorders who participated in a previous trial with evenamide. Pazienti con disturbi psichiatrici che hanno partecipato a una precedente sperimentazione con evenamide., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Recruiting | 2/3 | 180 | RoW | Idebenone, Coenzyme Q10 analogue, Placebo oral tablet | Second Affiliated Hospital, School of Medicine, Zhejiang University, Peking Union Medical College Hospital, Beijing Hospital, Beijing Tiantan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Jiangsu Province Nanjing Brain Hospital, The First Affiliated Hospital of Anhui Medical University, Huashan Hospital, Tongji Hospital, Second Affiliated Hospital of Soochow University, Guizhou Medical University, The First Affiliated Hospital of Guangzhou Medical University, Peking University Shenzhen Hospital, West China Hospital, Wuhan Union Hospital, China, Sir Run Run Shaw Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Dalian Medical University, Qilu Hospital of Shandong University | REM Sleep Behavior Disorder, Parkinson Disease | 01/22 | 01/23 | | |
ELEKT-D, NCT03113968: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) |
|
|
| Completed | 2/3 | 403 | US | electroconvulsive therapy (ECT), Ketamine | Bo Hu, Patient-Centered Outcomes Research Institute | Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine, Psychiatric Disorder, Depression, Major Depressive Disorder, Major Depressive Episode, Unipolar Depression | 10/22 | 11/22 | | |
NCT03485274: Substance Misuse To Psychiatric Disorders for Cannabis |
|
|
| Completed | 2/3 | 37 | RoW | Vortioxetine, Treatment as Usual | The University of Hong Kong, Queen Mary Hospital, Hong Kong | Cannabis Use Disorder, Depressive State, Anxiety State, Depression, Anxiety Disorders, Pharmacotherapy | 02/23 | 04/23 | | |
2021-001352-33: A clinical trial to assess the efficacy, safety, and tolerability of AVP-786 versus placebo for the treatment of negative symptoms of schizophrenia |
|
|
| Not yet recruiting | 2/3 | 370 | Europe | Deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q], AVP-786, Capsule, hard | Otsuka Pharmaceutical Development & Commercialization, Inc., Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc, Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Negative symptoms of schizophrenia, Negative symptoms of schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT03479476: A Trial of Metformin in Individuals With Fragile X Syndrome |
|
|
| Completed | 2/3 | 120 | Canada, US | Placebo Medication, Placebo, Metformin, Glumetza, Glucophage, Fortamet, Riomet | University of California, Davis, University of Alberta, St. Justine's Hospital | Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X Linked, Genetic Diseases, X-Linked, Trinucleotide Repeat Expansion, Fra(X) Syndrome, Intellectual Disability, FXS, Neurobehavioral Manifestations, Sex Chromosome Disorders | 12/23 | 05/24 | | |
MedCanDem, NCT05432206: MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva |
|
|
| Recruiting | 2/3 | 24 | Europe | Cannabis Sativa Oil, Placebo | Fondation pour l'accueil et l'hébérement des personnes âgées, University Hospital, Geneva | Dementia With Behavioral Disturbance | 09/24 | 09/24 | | |
NCT05611372: Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease |
|
|
| Not yet recruiting | 2/3 | 732 | NA | Rasagiline | Second Affiliated Hospital, School of Medicine, Zhejiang University, Beijing Tiantan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Jiangsu Province Nanjing Brain Hospital, The First Affiliated Hospital of Anhui Medical University, Huashan Hospital, Second Affiliated Hospital of Soochow University, Guizhou Medical University, The First Affiliated Hospital of Guangzhou Medical University, West China Hospital, Sir Run Run Shaw Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Dalian Medical University, Qilu Hospital of Shandong University, Fujian Medical University Union Hospital | REM Sleep Behavior Disorder, Parkinson Disease, Synucleinopathies | 12/25 | 12/26 | | |
MEL-QUE, NCT06062953: Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia |
|
|
| Recruiting | 2/3 | 255 | Europe | Melatonin, Quetiapine, Placebo | Lone Baandrup, Danish Center for Sleep Medicine, Region Capital Denmark, Copenhagen Trial Unit, Center for Clinical Intervention Research, Mental Health Services in the Capital Region, Denmark | Psychiatric Disorders, Insomnia | 02/26 | 02/26 | | |
